Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

NCT00052572 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Lymphoma

Interventions

DRUG: ixabepilone

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]